JPH04128235A - Mental fatigue preventing and removing agent - Google Patents
Mental fatigue preventing and removing agentInfo
- Publication number
- JPH04128235A JPH04128235A JP2249715A JP24971590A JPH04128235A JP H04128235 A JPH04128235 A JP H04128235A JP 2249715 A JP2249715 A JP 2249715A JP 24971590 A JP24971590 A JP 24971590A JP H04128235 A JPH04128235 A JP H04128235A
- Authority
- JP
- Japan
- Prior art keywords
- fennel oil
- minutes
- diffusing
- mental
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019914 Mental Fatigue Diseases 0.000 title claims abstract description 16
- 239000010643 fennel seed oil Substances 0.000 claims abstract description 68
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 210000004072 lung Anatomy 0.000 claims abstract description 7
- 210000002200 mouth mucosa Anatomy 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 210000002850 nasal mucosa Anatomy 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 206010042220 Stress ulcer Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 abstract description 10
- 230000003340 mental effect Effects 0.000 abstract description 9
- 240000006927 Foeniculum vulgare Species 0.000 abstract description 8
- 235000004204 Foeniculum vulgare Nutrition 0.000 abstract description 8
- 208000025865 Ulcer Diseases 0.000 abstract description 8
- 231100000397 ulcer Toxicity 0.000 abstract description 8
- 235000009508 confectionery Nutrition 0.000 abstract description 7
- 239000000341 volatile oil Substances 0.000 abstract description 7
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 abstract description 6
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 abstract description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 abstract description 4
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 abstract description 4
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 abstract description 3
- 229940011037 anethole Drugs 0.000 abstract description 3
- 235000015110 jellies Nutrition 0.000 abstract description 3
- 239000008274 jelly Substances 0.000 abstract description 3
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 abstract description 3
- 235000014214 soft drink Nutrition 0.000 abstract description 3
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 abstract description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 abstract description 2
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 abstract description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 abstract description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 abstract description 2
- 229930006739 camphene Natural products 0.000 abstract description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 abstract description 2
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 abstract description 2
- 229960005233 cineole Drugs 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 229940087305 limonene Drugs 0.000 abstract description 2
- 235000001510 limonene Nutrition 0.000 abstract description 2
- 238000001256 steam distillation Methods 0.000 abstract description 2
- 239000006190 sub-lingual tablet Substances 0.000 abstract description 2
- LHXDLQBQYFFVNW-UHFFFAOYSA-N Fenchone Chemical compound C1CC2(C)C(=O)C(C)(C)C1C2 LHXDLQBQYFFVNW-UHFFFAOYSA-N 0.000 abstract 2
- 210000000214 mouth Anatomy 0.000 abstract 2
- LHXDLQBQYFFVNW-XCBNKYQSSA-N (+)-Fenchone Natural products C1C[C@]2(C)C(=O)C(C)(C)[C@H]1C2 LHXDLQBQYFFVNW-XCBNKYQSSA-N 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 240000004760 Pimpinella anisum Species 0.000 abstract 1
- 235000012550 Pimpinella anisum Nutrition 0.000 abstract 1
- 229930006735 fenchone Natural products 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 229940098466 sublingual tablet Drugs 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 230000003547 miosis Effects 0.000 description 21
- 206010027646 Miosis Diseases 0.000 description 20
- 230000007423 decrease Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000004439 pupillary reactions Effects 0.000 description 11
- 230000000241 respiratory effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000001747 pupil Anatomy 0.000 description 7
- 230000000284 resting effect Effects 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 235000015205 orange juice Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- -1 Polyoxyethylene Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 238000000222 aromatherapy Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 2
- 229960002456 hexobarbital Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003304 psychophysiological effect Effects 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- LHXDLQBQYFFVNW-OIBJUYFYSA-N (-)-Fenchone Chemical compound C1C[C@@]2(C)C(=O)C(C)(C)[C@@H]1C2 LHXDLQBQYFFVNW-OIBJUYFYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FGYZAECYNNGYAN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;propane-1,2-diol Chemical compound CC(O)CO.OC(=O)CC(O)(C(O)=O)CC(O)=O FGYZAECYNNGYAN-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FMOUWNBVUJNNHE-XXAVUKJNSA-N CC(O)CO.OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound CC(O)CO.OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O FMOUWNBVUJNNHE-XXAVUKJNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000166652 Cymbopogon martinii Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000017304 Ruaghas Nutrition 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 241000758724 Schisandraceae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000004478 pupil constriction Effects 0.000 description 1
- 235000020071 rectified spirit Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- MFSDELSXOVOZBJ-UHFFFAOYSA-M sodium;dodecyl sulfate;propane-1,2,3-triol Chemical compound [Na+].OCC(O)CO.CCCCCCCCCCCCOS([O-])(=O)=O MFSDELSXOVOZBJ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VKVAIFBQDZULKS-PSBBUKMFSA-K trisodium (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound O=C1C(O)=C(O)[C@H](O1)[C@@H](O)CO.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] VKVAIFBQDZULKS-PSBBUKMFSA-K 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はフェンネル油を有効成分として含有する精神疲
労予防回復剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a mental fatigue prevention and recovery agent containing fennel oil as an active ingredient.
〔従来の技術及び発明が解決しようとする課題〕近年、
香りが生理、心理状態に種々の影響を与えるといった報
告が数多くなされており、香りの精神生理効果が注目さ
れるようになってきた。従来、香りにより精神的疲労を
予防又は回復する方法としては、ヨーロッパ地方におい
て古くからアロマテラピーが知られている(アロマテラ
ピーく芳香療法〉の理論と実際:ロバート・ティスラン
ト著、フレグランスジャーナル社1987)。[Problems to be solved by conventional techniques and inventions] In recent years,
There have been many reports that scents have various effects on menstruation and psychological conditions, and the psychophysiological effects of scents have been attracting attention. Traditionally, aromatherapy has been known in Europe for a long time as a method for preventing or recovering from mental fatigue using scents (The Theory and Practice of Aromatherapy): Robert Tisland, Fragrance Journal, 1987. ).
また、ウィキョウ(フェンネル)は漢方の安中敗、丁香
柿帝湯の2処方に配合されており、敗寒薬、即ち血管拡
張、血行促進、中枢興奮、局所刺激等による身体全体あ
るいは局所を温める効果があるとされている(図説漢方
処方の構成と適用、森雄材著、医歯薬出版、1977)
。ウィキョウより得られる精油であるフェンネル油(ウ
ィキョウ油)については、健胃、駆風、社痰作用(新訂
和漢薬、赤松金芳著、医歯薬出版、1970) 、また
その主成分であるアネトールについてはモルモット摘出
腸管収縮作用(令聞和泉、北畠芳子:薬学雑誌、82.
1326〜1328頁、 1962)が知られており、
さらにフェンネル末については、600 mg/ kg
の経口投与で35〜39%の潰瘍抑制効果が認められた
ことが報告されている(山原條二、沢田徳之助、藤村−
二第4回天然薬物の開発と応用シンポジウム、68〜7
0頁、19B2)。また、ウィキョウのその他の薬理作
用の考察についても、伊東らによる詳しい報告があるが
〔伊東ら、現代東洋医学、9.Nα3゜57〜63頁、
1988) 、フェンネル油の香りによる精神生理効
果についての報告はない。In addition, fennel is included in two Chinese herbal medicine prescriptions, Anchuhe and Chokogakiteito, and is used as an anti-cold medicine, warming the entire body or local areas by dilating blood vessels, promoting blood circulation, central stimulation, and local stimulation. It is said to be effective (Illustrated composition and application of Chinese herbal prescriptions, written by Yuzai Mori, Ishiyaku Publishing, 1977)
. Fennel oil (fennel oil), which is an essential oil obtained from fennel, has stomachic, carminative, and phlegm effects (Newly revised Japanese and Chinese Medicine, written by Kinyoshi Akamatsu, Ishiyaku Publishing, 1970), and its main component. Anethole has been shown to have an intestinal constriction effect in isolated guinea pigs (Izumi Reimon, Yoshiko Kitabatake: Pharmaceutical Journal, 82.
1326-1328, 1962) is known,
Furthermore, for fennel powder, 600 mg/kg
It has been reported that oral administration of 35-39% ulcer suppressive effect was observed (Joji Yamahara, Tokunosuke Sawada, Fujimura-
24th Natural Drug Development and Application Symposium, 68-7
0 page, 19B2). There is also a detailed report by Ito et al. regarding other pharmacological effects of fennel [Ito et al., Modern Oriental Medicine, 9. Nα3゜pages 57-63,
(1988), there are no reports on the psychophysiological effects of the scent of fennel oil.
このような実情において、本発明者らは多くの香気物質
について、その生理作用に及ぼす影響を試験していたと
ころ、フェンネル油を鼻粘膜、口腔粘膜又は肺から吸収
させて投与すると、速効性をもって、かつ低濃度で精神
的ストレスにより生ずる疲労及びこれに伴って発生する
ストレス潰瘍が予防ないし回復されることを見出し、本
発明を完成した。Under these circumstances, the present inventors tested the effects of many aromatic substances on their physiological effects, and found that when fennel oil was absorbed and administered through the nasal mucosa, oral mucosa, or lungs, it had a rapid effect. The present invention has been completed based on the discovery that, at low concentrations, fatigue caused by mental stress and stress ulcers that occur accompanying this can be prevented or cured.
従って、本発明は、フェンネル油を有効成分として含有
し、該有効成分が鼻粘膜、口腔粘膜又は肺から吸収され
るような形態に製剤化されていることを特徴とする精神
疲労予防回復剤を提供するものである。Therefore, the present invention provides a mental fatigue prevention and recovery agent, which contains fennel oil as an active ingredient and is formulated in a form that allows the active ingredient to be absorbed through the nasal mucosa, oral mucosa, or lungs. This is what we provide.
フェンネル油はウィキョウ、Poen icu lum
vulgare Miller (Umbelifer
ae)又はIlliciumverum Hooker
fil、 (Illiciaceae)の果実を水蒸
気蒸留して得られる精油で、アネトールを主成分(50
%以上)とし、その他にα−ピネン、カンフエン、リモ
ネン、シネオール、p−シメン、フェンチョン、アニス
アルデヒドを含有するものである。そして、このものは
、例えば第11改正日本薬局方第二部にも収載されてい
る。Fennel oil comes from fennel, Poen icu lum
Vulgare Miller (Umbelifer)
ae) or Illicium verum Hooker
fil, (Illiciaceae) is an essential oil obtained by steam distillation of the fruit, and contains anethole as the main component (50
% or more) and also contains α-pinene, camphene, limonene, cineole, p-cymene, fenchon, and anisaldehyde. This product is also listed in Part 2 of the 11th edition of the Japanese Pharmacopoeia, for example.
このフェンネル油は後述の有効濃度を与えることができ
るものであれば如何なる純度のものでもよく、またこれ
は、その作用が損われない範囲において他の成分、例え
ばベルガモツト、レモン、バラ、ジンジャ−、グレープ
フルーツ、ネロリ、パルマローザ、タラリセージ、ロー
ズマリー、ナツメグ、カミツレ、マジョラム、ラベンダ
ー、ゼラニウム、サンダルウツド、ベチバー、ジコニパ
ー等の香気物質と混合して使用することもできる。This fennel oil may be of any purity as long as it can provide the effective concentration described below, and it may contain other ingredients such as bergamot, lemon, rose, ginger, etc. to the extent that its action is not impaired. It can also be used in combination with aromatic substances such as grapefruit, neroli, palmarosa, tarari sage, rosemary, nutmeg, chamomile, marjoram, lavender, geranium, sandalwood, vetiver, and ziconiper.
本発明の精神疲労予防回復剤の効果は、フェンネル油が
鼻粘膜、口腔粘膜又は肺から吸収されることによって奏
されるものであるから、本発明の精神疲労予防回復剤は
フェンネル油がそのような吸収可能な形態に製剤化され
ていることが必要である。製剤化の方法は特に制限され
ず、フェンネル油の香気成分が鼻粘膜、口腔粘膜又は肺
から吸収され墨ようにすればよい。斯かる形態としては
、空気中に拡散させて吸入させるスプレー剤、揮散性芳
香剤、あるいは口中に拡散させて吸収させるガム、飴等
の菓子類、トローチ、洗口液、ゼリーリキュール等のア
ルコール類、清涼飲料、舌下錠又はコーヒー、紅茶等に
添加して使用する添加剤等が挙げられる。さらに、フェ
ンネル油をマイクロカプセルに封入し用いてもよい。The effects of the agent for preventing and recovering from mental fatigue of the present invention are achieved when fennel oil is absorbed through the nasal mucosa, oral mucosa, or lungs. It is necessary that the drug be formulated in a form that can be easily absorbed. The formulation method is not particularly limited, and it is sufficient that the aromatic components of fennel oil are absorbed through the nasal mucosa, oral mucosa, or lungs to form an ink-like formulation. Examples of such forms include sprays that are diffused into the air and inhaled, volatile fragrances, and confectionery such as gums and candies that are diffused into the mouth and absorbed, alcoholic products such as troches, mouth washes, and jelly liqueurs. , soft drinks, sublingual tablets, or additives added to coffee, tea, etc. Furthermore, fennel oil may be encapsulated in microcapsules.
空中に拡散させて吸入させる形態のものの場合には、本
発明の効果を奏させるために、フェンネル油の空気中濃
度が少なくとも0.45ng/ 1以上になるようにす
る。これを超えてさらに濃度を高くしても然程の効果の
増大は認められないので、通常は0.45〜9. On
g/ 1となるように調製するのが好ましい。このため
には、スプレー剤にあっては、アルコール等の溶剤に0
.1〜lO%濃度にとかし、噴射剤と共に容器に充填す
るのが、また揮散性芳香剤にあっては、常法によって、
イソパラフィン等の溶液又はゲル中に溶解ないし分散さ
せるのが好ましい。In the case of a type of fennel oil that can be diffused into the air and inhaled, the concentration of fennel oil in the air should be at least 0.45 ng/1 in order to achieve the effects of the present invention. Even if the concentration is increased further beyond this, no appreciable increase in effect will be observed, so it is usually 0.45 to 9. On
It is preferable to adjust the ratio to 1 g/1. For this purpose, when using a spray agent, it is necessary to use a solvent such as alcohol.
.. For volatile fragrances, it is dissolved to a concentration of 1 to 10% and filled into a container with a propellant, or by a conventional method.
It is preferable to dissolve or disperse it in a solution or gel such as isoparaffin.
さらにまた、日中で拡散させる□形態のものの場合に、
は、フェンネル油が4.5 xlO−’%以上になるよ
うに含有させればよい。Furthermore, in the case of □ type that diffuses during the day,
may be contained in an amount of 4.5 x lO-'% or more of fennel oil.
本発明の精神疲労予防回復剤及び潰瘍予防治療剤の作用
は以下の方法により評価した。The effects of the mental fatigue prevention and recovery agent and the ulcer prevention and treatment agent of the present invention were evaluated by the following methods.
精神的疲労の測定:
くヒトによる客観生理評価〉
(イ)人間に精神的なストレスを与える作業、例えば、
パソコンによる計算作業課題負荷を与えたときの心拍間
隔の変動の程度、あるいは、心拍間隔の呼吸性の変動成
分の変化の程度により評価する。ストレス作業時の自律
神経機能と心拍間隔の変動との関係については、5ay
ersらの実験で証明されている。[8,ilc^、5
ayars、 Brgonomics、 16゜p1
7〜32.1973゜中垣、岩田、広瀬、石井0日本機
械学会論文誌、 53. p2699〜2702 (昭
和62年)、寺下、大須賀、開部、第53回日本心理学
会論文集。Measurement of mental fatigue: Objective physiological evaluation by humans (a) Work that causes mental stress on humans, e.g.
Evaluation is based on the degree of variation in the heartbeat interval or the degree of change in the respiratory component of the heartbeat interval when a computer-based calculation task load is applied. Regarding the relationship between autonomic nervous function and heart rate interval variation during stress work, 5ay
This has been proven in experiments by Ers et al. [8,ilc^,5
ayars, Brgonomics, 16°p1
7-32.1973゜Nakagaki, Iwata, Hirose, Ishii0 Journal of the Japan Society of Mechanical Engineers, 53. p2699-2702 (1988), Terashita, Osuga, Kaibe, Proceedings of the 53rd Japanese Psychological Association.
p878.1989、永井、中川、三宅、朝食、第23
回味と匂いのシンポジウム論文集、p55〜58.19
89]。p878.1989, Nagai, Nakagawa, Miyake, Breakfast, No. 23
Proceedings of Symposium on Taste and Smell, p55-58.19
89].
単純計算作業時には、交感神経系の興奮、副交感神経系
の抑制に伴う心拍間隔の変動の減少が生じ、またストレ
ス作業負荷の直前、直後では、副交感神経系の興奮によ
る心拍間隔変動の増加が生じるが、これらの反応が香り
を与えることにより抑制されるか否かにより評価できる
。During simple calculation tasks, a decrease in heart rate variability occurs due to excitation of the sympathetic nervous system and inhibition of the parasympathetic nervous system, and an increase in heart rate interval variability occurs due to excitation of the parasympathetic nervous system immediately before and after a stressful workload. However, evaluation can be made based on whether these reactions are suppressed by providing a scent.
(ロ)人間に精神的なストレスを与える作業、例えばパ
ソコンによる計算作業課題負荷を与えたときの瞳孔の収
縮反応の低下により評価する。ストレス時の瞳孔の光に
よる収縮反応が抑制されることは、ルイーズ・プロフィ
−等の実験で証明されている。(Louise Plo
uffe and Robert M。(b) Evaluate by the decrease in pupil constriction response when tasks that cause mental stress to humans are performed, such as computer calculation tasks. It has been proven in experiments by Louise Profy et al. that the constriction reaction of the pupils due to light during stress is suppressed. (Louise Plo
uffe and Robert M.
Stelmack、 Perceptual an
d Motor 5kill、 ↓l。Stelmack, Perceptual an
d Motor 5kill, ↓l.
p635〜642.1979 、中川、永井、三宅、朝
食、第23回味と匂いのシンポジウム論文集、 p30
5〜308゜1989)。また、瞳孔の光による収縮反
応と自律神経機能の相関関係は、内海による実験で解明
されている(内海隆、日限会誌、 83. p1524
〜1528゜昭和54年)。ストレス作業負荷直前なら
びに終了直後に灯光瞳孔反応を測定すれば、副交感神経
系の興奮により瞳孔の縮瞳機能の低下が認められるが、
これらの反応が香りを与えることにより抑制されるか否
かにより評価できる。p635-642.1979, Nakagawa, Nagai, Miyake, Breakfast, Proceedings of the 23rd Taste and Smell Symposium, p30
5-308°1989). In addition, the correlation between the constriction reaction of the pupil due to light and the autonomic nervous function was clarified through experiments by Utsumi (Takashi Utsumi, Daily Journal, 83. p1524)
~1528°1972). If the pupillary response to light is measured immediately before and after the stress workload, a decline in the miotic function of the pupil due to the excitement of the parasympathetic nervous system is observed;
Evaluation can be made based on whether these reactions are suppressed by providing a scent.
くヒトによる主観心理評価〉
人間に精神的なストレスを与える作業、例えばパソコン
による計算作業課題負荷を与えたときの主観的心理尺度
の変化により評価する。心理尺度には、Mc Ni1r
e等が開発したProfile of MoodSta
te(POMS、気分状態尺度)を用いる(Mc Ni
1ireet al、 An Analysis of
Mood in Neurotics、 J。Subjective psychological evaluation by humans> Evaluation is based on changes in subjective psychological scales when humans are subjected to tasks that cause mental stress, such as computational work on a computer. Psychological scales include McNi1r
Profile of MoodSta developed by e etc.
te (POMS, Mood State Scale) (Mc Ni
1ireet al, An Analysis of
Mood in Neurotics, J.
^bnomal and 5ocial Psy
chology、 69. 620゜1964)。ス
トレス作業負荷の前後で生じた心理状態の変化を精油の
香りの投与の有無により比較することで、ストレス時の
主観的な自覚症状の改善が認められたかを評価できる。^bnormal and 5ocial Psy
chology, 69. 620°1964). By comparing the changes in psychological state before and after stress workload with and without the administration of essential oil scents, it is possible to evaluate whether subjective symptoms during stress have improved.
くマウスを用いた評価〉
(イ)マウスの自発運動量の増減をアンビュロメーター
により評価する。アンビュロメーターによる自発運動量
の変化と中枢作用の相関は、平林らによって明らかにさ
れている(平林、飯塚、田所、日薬理誌、74、p62
9〜639 (1978))。精油の香りを与えた場合
に明らかな自発運動量の低下が認められれば、中枢抑制
、すなわち鎮静作用が認められると結論できる。Evaluation using mice (a) Evaluate the increase or decrease in spontaneous locomotor activity of mice using an ambulometer. The correlation between changes in locomotor activity measured by an ambulometer and central effects was clarified by Hirabayashi et al. (Hirabayashi, Iizuka, Tadokoro, Japanese Pharmacological Journal, 74, p.
9-639 (1978)). If a clear decrease in locomotor activity is observed when the aroma of essential oils is given, it can be concluded that a central depression, or sedative effect, is observed.
(ロ)マウスに水浸拘束ストレス負荷を与えた際に生じ
たストレス性の胃潰瘍の程度により評価する。マウスを
首から下の部分を水に浸は拘束し、精油の香りを与えた
時と与えない時の潰瘍発現率を解剖所見で判定した。(b) Evaluate based on the degree of stress-induced gastric ulcers that occur when mice are subjected to water immersion restraint stress. Mice were restrained by immersing them in water from the neck down, and the incidence of ulcers was determined based on autopsy findings when the scent of essential oil was applied and when it was not.
(ハ)マウスのへキソバルビタールによって誘発される
睡眠時間が精油の香りを与えることによって延長される
か否かで評価する。中枢抑制、すなわち鎮静作用があれ
ば誘発された睡眠時間は延長される。(c) Evaluate whether or not the sleeping time induced by hexobarbital in mice is prolonged by providing the scent of essential oil. Central depression, or sedation, prolongs the duration of induced sleep.
次に実施例を挙げて説明する。 Next, an example will be given and explained.
実施例1
被験者4名を用い、恒温(24℃)、恒温(60%)の
電磁シールドルーム内に入れ、10分間の安静状態での
心電図を測定した。測定終了後、計算作業負荷直前の灯
光瞳孔反応を測定し、その時の心理状態を自己申告制ア
ンケートに記述させた。Example 1 Four subjects were placed in an electromagnetic shield room with constant temperature (24° C.) and constant temperature (60%), and their electrocardiograms were measured in a resting state for 10 minutes. After the measurement was completed, the pupillary reaction to light was measured immediately before the computational workload, and the subjects were asked to describe their psychological state at that time in a self-report questionnaire.
次に10分間記述式の計算課題(クレペリン計算作業)
を3回、計30分間行わせて精神的疲労を与え、その間
の心電図を記録し、10分毎に作業を中断して、灯光瞳
孔反応を測定した。その後、計算負荷終了後の心理状態
を自己申告制アンケートに記述させた。その後、さらに
30分間安静にし、疲労回復状態を測定した。この試行
を各被験者についてフェンネル油を投与した場合と投与
しない場合の2回にわたって行った。フェンネル油の投
与は、フェンネル油(長谷用香料、S^5057) 3
atl!を流動パラフィン30m1に溶かしてガス洗浄
ビンに入れ、外部より61/分の空気を送りこんで試験
開始前よりシールドルーム内のフェンネル油の空気中濃
度が13.5ng/ 1になるように放散させることに
よって行った。Next, a 10-minute written calculation task (Kraepelin calculation work)
This was performed three times for a total of 30 minutes to induce mental fatigue, and electrocardiograms were recorded during this period, and the task was interrupted every 10 minutes to measure light pupillary reactions. Afterwards, the participants were asked to describe their psychological state after completing the calculation load using a self-report questionnaire. Thereafter, the subjects were allowed to rest for an additional 30 minutes, and their state of recovery from fatigue was measured. This trial was conducted twice for each subject, once with and without fennel oil. Administration of fennel oil: Fennel oil (Fragrance for Hase, S^5057) 3
atl! Dissolve fennel oil in 30 ml of liquid paraffin, place it in a gas cleaning bottle, and blow in air from the outside at 61 ng/min to dissipate the fennel oil in the air in the shield room to a concentration of 13.5 ng/min before the start of the test. It was done by
(i)心拍間隔の変動
胸部、左足首より導出した心電図を時定数0.1秒、ハ
イカットフィルター10)1zテj1幅(日本電気三栄
社製、多用途ポリグラフmodel 363)L、得ら
れた心電図波形からR波を自動検出し、R−R間隔を算
出した(日本電気三栄社製、シグナルプロセッサー77
18)。(i) Changes in heartbeat interval The electrocardiogram derived from the chest and left ankle was measured using a time constant of 0.1 seconds, a high-cut filter 10) 1z width (manufactured by NEC Sanei Co., Ltd., multipurpose polygraph model 363) L, and the obtained electrocardiogram The R wave was automatically detected from the waveform and the R-R interval was calculated (Signal Processor 77, manufactured by NEC Sanei Co., Ltd.
18).
このR−R間隔データより、次式によって求められる1
0分間の心拍間隔変動係数([”Vi−i)を指標とし
てフェンネル油投与群と非投与群を比較した。From this R-R interval data, 1 is calculated by the following formula.
The fennel oil administration group and the non-administration group were compared using the 0 minute heart rate interval variation coefficient ([''Vi-i) as an index.
安静時(B、 L口^口)の10分間の心拍間隔変動係
数を100とし、計算作業中0〜lO分(0゜LOAD
IO) 、 10〜20分 (0,Lロ^ロ20) 、
20〜30分(D、LOAD30)及び計算後の安静
時0〜lO分(A。The heartbeat interval variation coefficient for 10 minutes at rest (B, L mouth) is set as 100, and during calculation work 0 to 10 minutes (0°LOAD
IO), 10-20 minutes (0,Lro^ro20),
20-30 minutes (D, LOAD30) and 0-10 minutes at rest after calculation (A.
LOADIO) 、10〜20分(^、LO八〇2へ)
の心拍間隔変動係数を比較した結果は、第1図のとおり
である。第1図が示すように、フェンネル油非投与群で
は、単純記述式計算作業中の緊張に伴い、心拍間隔変動
係数が減少するが、フェンネル油投与群ではこの作用が
抑制されて、心拍間隔変動係数が非投与群に比べ危険率
20%以内の有意差をもって増加しており、計算作業中
の精神疲労が軽減されていることが確認できた。LOADIO), 10-20 minutes (^, to LO 802)
The results of comparing the heartbeat interval variation coefficients are shown in FIG. As shown in Figure 1, in the fennel oil non-administered group, the heart rate interval variation coefficient decreases due to stress during simple descriptive calculation work, but in the fennel oil administered group, this effect is suppressed and the heart rate interval variation decreases. The coefficient increased with a significant difference within 20% of the risk rate compared to the non-administered group, confirming that mental fatigue during calculation work was reduced.
(ii)射光瞳孔反応
オープンループ型赤外線双眼イリスコーダ(浜松フォト
ニクス製C2515)を用い、刺激強度l/2、光刺激
点灯時間0.25秒で右目に光刺激を与え、その時の右
目の瞳孔反応を光刺激後4.25秒間計測した。得られ
た瞳孔面積の時系列データから、縮瞳率(Cll)を次
式のように算出した。(ii) Optical pupillary response Using an open-loop infrared binocular iris coder (C2515 manufactured by Hamamatsu Photonics), a light stimulus was applied to the right eye at a stimulus intensity of 1/2 and a light stimulus lighting time of 0.25 seconds, and the pupillary response of the right eye at that time was measured. Measurement was performed for 4.25 seconds after light stimulation. From the obtained time series data of the pupil area, the miosis rate (Cll) was calculated as shown in the following formula.
射光瞳孔反応は、連続して3回計測し、得られた縮瞳率
の3回の加算平均値をその時点での縮瞳率とした。The pupillary reaction to light was measured three times in succession, and the average value of the three times of the obtained miosis rate was taken as the miosis rate at that point.
安静時(0分)での縮瞳率を100とし、計、算作業開
始lO分、20分、30分後及び計算終了後の安静時1
0分、20分の縮瞳率を比較した結果は、第2図のとお
りである。第2図から明らかな如く、フェンネル油を投
与しない対照群では、計算作業による精神的疲労の蓄積
により縮瞳率の低下がみられ、作業終了後もすぐには回
復しないが、フェンネル油投与群では計算作業による縮
瞳率の低下はほとんど認められず、フェンネル油が眼精
疲労の予防効果を有することが明らかである。The miosis rate at rest (0 minutes) is assumed to be 100, and the calculation is performed at 10 minutes, 20 minutes, 30 minutes after the start of calculation work, and at rest 1 after the end of calculation.
The results of comparing the miosis rates at 0 minutes and 20 minutes are shown in FIG. As is clear from Figure 2, in the control group to which fennel oil was not administered, the miosis rate decreased due to the accumulation of mental fatigue due to calculation work, and did not recover immediately after the work was completed, but in the control group to which fennel oil was not administered. There was almost no decrease in the miosis rate due to calculation work, and it is clear that fennel oil has a preventive effect on eye strain.
(ii )心理状態
計算作業の前後にあける心理状態を、緊張、抑圧、怒り
、活力、疲労、混乱の要因について、Mc Ni1re
ら:^n Analysis of Mood 1nN
eurotics、 J、^bnora+al and
SocialPhychology、 69.620
.1964に記載の方法によって行った。その結果は第
3図のとおりである。第3図から、緊張、抑圧、怒り、
疲労、混乱の各要因に関して抑制傾向にあることが認め
られた。(ii) Psychological state McNi1re explains the psychological states that occur before and after calculation work, including tension, depression, anger, vitality, fatigue, and confusion.
et al: ^n Analysis of Mood 1nN
eurotics, J, ^bnora+al and
Social Physics, 69.620
.. The method described in 1964 was used. The results are shown in Figure 3. From Figure 3, tension, repression, anger,
It was observed that there was a tendency to suppress the factors of fatigue and confusion.
実施例2
被験者12名を用い、恒温(24℃)、恒温(60%)
の電磁シールドルーム内に入れ、10分間の安静状態で
の心電図を測定した。測定終了後、安静状態の射光瞳孔
反応を測定し、その時の心理状態を自己申告制アンケー
トに記述させた。続いて、計算作業開始直前の10分間
の心電図を測定し、続いて計算作業開始直前の射光瞳孔
反応を測定した。Example 2 Using 12 subjects, constant temperature (24°C), constant temperature (60%)
The subjects were placed in an electromagnetically shielded room, and their electrocardiograms were measured during a 10-minute period of rest. After the measurements were completed, the resting state pupillary response was measured, and the subjects were asked to describe their psychological state at that time in a self-report questionnaire. Subsequently, an electrocardiogram was measured for 10 minutes immediately before the start of the calculation task, and subsequently, the light emitting pupillary response immediately before the start of the calculation task was measured.
次に、パーソナルコンビコータを用いたキーボード入力
式の計算作業課題を4回連続で計40分間実施した。こ
の計算作業課題は被験者の計算作業に対する慣れを防ぐ
目的で、10分毎に問題が難しくなるように作成した。Next, a keyboard-input calculation task using a personal Combi coater was performed four times in a row for a total of 40 minutes. This calculation work task was created so that the questions became more difficult every 10 minutes in order to prevent the subjects from getting used to the calculation work.
また、課題作業は40秒で20間解答するようにできて
おり、解答入力が間にあわない場合には、次の20間が
提示され、被験者は不達成感を味わいながらコンピュー
タのペースで作業を行うことをしいられるように工夫さ
れている。この40分間の計算作業課題中の心電図を測
定し、計算終了後ただちに、射光瞳孔反応を測定すると
共に心理状態を自己申告制アンケートに記述させた。そ
の後さらに、先はどと同様の計算作業課題を行わせ、そ
の間の心電図を計測し、計算作業終了後、ただちに射光
瞳孔反応を測定した。この作業終了後、さらに20分間
の安静状態を測定し、疲労回復状態を測定し、心理状態
を自己申告制アンケートに記述させた。この試行を各被
験者について、フェンネル油を投与した場合と投与しな
い場合の2回にわたって行った。In addition, the task task is designed to be answered in 40 seconds for 20 periods, and if the answer is not entered in time, the next 20 periods will be presented, and the subject will work at the computer's pace while feeling a sense of failure. It is designed to help you learn things. Electrocardiograms were measured during the 40-minute calculation task, and immediately after the calculation was completed, the pupillary reaction to light was measured and the subjects were asked to describe their psychological state in a self-report questionnaire. Afterwards, the subjects were asked to perform the same calculation task as previously, and their electrocardiograms were measured during this period, and their pupillary responses to light were measured immediately after the calculation task was completed. After completing this task, the resting state was measured for another 20 minutes, the state of recovery from fatigue was measured, and the psychological state was described in a self-report questionnaire. This trial was conducted twice for each subject, once with and without fennel oil.
フェンネル油の投与は、フェンネル油(長谷用香料、S
^−5057) 1 iffを流動パラフィン30−に
溶かしてガス洗浄ビンに入れ、外部より61/分の空気
を送りこんで計算作業開始10分前の安静時よりシール
ドルーム内に放散させ、シールドルーム内のフェンネル
油の空気中濃度が4.5回g/ 1になるように放散さ
せることによって行った。The administration of fennel oil is fennel oil (Fragrance for Hase, S
^-5057) Dissolve 1 if in liquid paraffin 30- and put it in a gas cleaning bottle, blow in air from the outside at 61/min, and let it diffuse into the shield room from a resting state 10 minutes before starting calculation work. This was done by dispersing fennel oil so that the concentration in the air was 4.5 times g/1.
(i)心拍間隔の呼吸性変動
胸部、左足首より導出した心電図を時定数0.1秒、ハ
イカットフィルター10Hzで増幅(日本電気三栄社製
、多用途ポリグラフmodel 363) L、得られ
た心電図波形からR波を自動検出し、R−R間隔を算出
した(日本電気三栄社製、シグナルプロセッサー7T1
B)。(i) Respiratory variation in heartbeat interval The electrocardiogram derived from the chest and left ankle was amplified with a time constant of 0.1 seconds and a high-cut filter of 10 Hz (manufactured by NEC Sanei Co., Ltd., multipurpose polygraph model 363) L, the obtained electrocardiogram waveform The R-wave was automatically detected from the
B).
このR−R間隔の時系列データを3次のラグランジェ補
間法により等M隔に再サンプリングし、ファースト・フ
ーリエ変換法(FPT)により100秒毎に512ポイ
ントで周波数解析を行った。得られた周波数分布のパワ
ースペクトルデータから呼吸性変動成分を含む0.15
〜0、50Hzのトータルパワー値を求め、この心拍間
隔呼吸性変動成分(R3^成分)を指標として、フェン
ネル油投与群と非投与群を比較した。This RR interval time series data was resampled at equal M intervals using the third-order Lagrange interpolation method, and frequency analysis was performed at 512 points every 100 seconds using the fast Fourier transform method (FPT). 0.15 including the respiratory fluctuation component from the power spectrum data of the obtained frequency distribution.
The total power values at ~0 and 50 Hz were determined, and the fennel oil administration group and non-administration group were compared using this heart rate interval respiratory variation component (R3^ component) as an index.
なお100秒毎の心拍間隔呼吸性変動成分は、500秒
分すなわち連続5デ一タ分加算平均され、その平均値を
その時点での心拍間隔呼吸性変動成分とした。Note that the heartbeat interval respiratory variation component for every 100 seconds was added and averaged for 500 seconds, that is, for 5 consecutive data, and the average value was taken as the heartbeat interval respiratory variation component at that point.
安静時(RBSTI)の心拍間隔呼吸性変動成分を基準
とし、計算作業直前(RIllST2)、計算作業中0
〜10分(LD^Di) 、10〜20分(LOAD2
)、20〜30分(LOAD3)、30〜40分(LO
AD4)、40〜50分(LOAD5)、50〜60分
(L口^口6)及び計算後の安静時0〜10分(RBS
T3) 、10〜20分(RBST4)の心拍間隔呼吸
性変動成分の増減を比較した結果は、第4図の通りであ
る。第4図が示すように、フェンネル油非投与群では、
計算作業直前ならびに終了後に精神的ストレスに伴う抑
圧感等が増加するために副交感神経系の活動が賦活され
、呼吸性変動成分が増加するが、フェンネル油投与群で
は、呼吸性変動成分が非投与群に比べ有意差をもって減
少しており、計算作業直前の不安感や、作業終了後の精
神疲労が軽減されることが確認できた。Based on the resting state (RBSTI) heart rate interval respiratory variation component, immediately before calculation work (RIllST2), during calculation work 0
~10 minutes (LD^Di), 10-20 minutes (LOAD2
), 20-30 minutes (LOAD3), 30-40 minutes (LOAD3),
AD4), 40-50 minutes (LOAD5), 50-60 minutes (L mouth ^ mouth 6) and 0-10 minutes at rest after calculation (RBS
The results of comparing the increases and decreases in the heartbeat interval and respiratory fluctuation components between T3) and 10 to 20 minutes (RBST4) are shown in FIG. As shown in Figure 4, in the fennel oil non-administered group,
Immediately before and after calculation work, the feeling of depression associated with mental stress increases, which activates the activity of the parasympathetic nervous system and increases the respiratory variable component, but in the fennel oil administration group, the respiratory variable component increases. There was a significant decrease compared to the group, and it was confirmed that anxiety immediately before calculation work and mental fatigue after completing the work were reduced.
(ii )射光瞳孔反応 実施例1の(i)と同様にして測定した。(ii) Light pupillary response It was measured in the same manner as in Example 1 (i).
安静時(−1O分)での縮瞳率を基準として、計算作業
開始直前(0分)、40分計算作業終了後(40MIN
LOAD) 、60分計算作業終了後(60MIN
LOAD)、計算作業終了後の安静時10分後(IOM
IN RBST>、20分後(20MIN REST)
の縮瞳率の増減を比較した結果は第5図のとおりである
。第5図から明らかな如く、フェンネル油を投与しない
対照群では計算作業による精神的疲労の蓄積により縮瞳
率の低下がみられるが、フェンネル油投与群では、40
分計算作業終了後に縮瞳率の低下が有意差をもって抑制
されていることが確認できた。また、瞳孔面積の時系列
データから求められた縮瞳最高速度(Vc)についても
縮瞳率と同様に3回の加算平均値をその時点での縮瞳最
高速度とし、安静時を基準として計算作業開始直前、計
算作業終了直後、計算作業終了後安静時の縮瞳最高速度
の増減を比較した結果は第6図のとおりである。縮瞳率
と同様に7工ンネル油投与群では、40分計算作業終了
後に有意差をもって縮瞳最高速度の低下が抑制されるこ
とが確認できた。Based on the miosis rate at rest (-10 minutes), immediately before the start of calculation work (0 minutes), after 40 minutes of calculation work (40 MIN),
LOAD), after 60 minutes of calculation work (60MIN
LOAD), 10 minutes after resting after completing the calculation task (IOM
IN RBST>, 20 minutes later (20MIN REST)
The results of comparing the increases and decreases in the miosis rate are shown in FIG. As is clear from Figure 5, in the control group to which fennel oil was not administered, the miosis rate decreased due to the accumulation of mental fatigue due to calculation work, but in the fennel oil-administered group, the miosis rate decreased by 40.
It was confirmed that the decrease in the miosis rate was significantly suppressed after the minute calculation task was completed. In addition, for the maximum velocity of miosis (Vc) obtained from time-series data of pupil area, the average value of the three measurements is taken as the maximum velocity of miosis at that time, and the calculation is based on the resting state. Figure 6 shows the results of comparing the increases and decreases in the maximum velocity of miosis immediately before the start of the work, immediately after the end of the calculation work, and at rest after the end of the calculation work. As with the miosis rate, it was confirmed that in the 7-channel oil administration group, the decrease in the maximum velocity of miosis was suppressed with a significant difference after 40 minutes of calculation work.
(ii)心理状態 実施例1の(iii )と同様にして測定した。(ii) Mental state Measurement was performed in the same manner as in Example 1 (iii).
その結果は第7図のとおりである。第7図から、緊張、
抑圧、疲労の各要因に関して抑制傾向にあることが認め
られた。特に精神的ストレスの指標となる抑圧、疲労に
関しては、フェンネル油投与群では、有意差をもって抑
制されていることが確認できた。The results are shown in Figure 7. From Figure 7, tension,
It was observed that there was a tendency to suppress each factor of suppression and fatigue. In particular, it was confirmed that depression and fatigue, which are indicators of mental stress, were significantly suppressed in the fennel oil administration group.
実施例3
フェンネル油(実施例1と同じ) toId!を直径5
501mの濾紙(TOY口ADVANTBC5^)に含
浸させ、測定容器(群大式アンビュロメーター、小原医
科産業)に入れた。この中に、ddy雄性マウス(8週
齢)を入れて放置し、30分間の運動量をアンビュロメ
ーターでカウントし、フェンネル油含浸濾紙を入れない
場合と比較した。その結果は第8図に示すとおりであり
、フェンネル油の投与により、有意の運動量の低下が認
められた。Example 3 Fennel oil (same as Example 1) toId! diameter 5
A 501 m filter paper (TOY mouth ADVANTBC5^) was impregnated with the solution and placed in a measurement container (Gundai type ambulometer, Ohara Medical Sangyo). A ddy male mouse (8 weeks old) was placed in this and left to stand, and the amount of movement for 30 minutes was counted using an ambulometer, and compared with a case in which no fennel oil-impregnated filter paper was placed. The results are shown in FIG. 8, and a significant decrease in locomotor activity was observed by administration of fennel oil.
実施例4
直径55IIIII+ノ濾紙(↑ロYロADVANT[
![’ 5^)にフェンネル油(実施例1と同じ)50
I又は300Iを含浸させ、これを水を張ったインツル
−ジョンボックス内に置いた。この中で、ddy系雄性
マウス(6週齢)に水浸拘束ストレス負荷を与え、5時
間放置後、胃を摘出し、切開して胃壁を観察し、潰瘍係
数で評価した。Example 4 Diameter 55III + filter paper (↑RoYRoADVANT [
! [' 5^) and fennel oil (same as Example 1) 50
It was impregnated with I or 300 I and placed in an infusion box filled with water. Among them, ddy male mice (6 weeks old) were subjected to water immersion restraint stress, and after being left for 5 hours, the stomach was removed and incised to observe the gastric wall and evaluated by ulcer index.
潰瘍係数1:正常胃に近い状態
2:出血がほとんどなく粘膜上皮が壊
死して白色化した状態
3:出血が部分的にみられ両表面が所
々赤色化した状態
4:出血がひどく両表面が赤色化し、
ただれた状態
その結果は第9図に示すとおりであり、フェンネル油の
投与により潰瘍の形成が有意に抑制された。Ulcer coefficient 1: Condition similar to normal stomach 2: There is almost no bleeding and the mucosal epithelium is necrotic and white. 3: Bleeding is partially observed and both surfaces are red in places. 4: Bleeding is severe and both surfaces are The result was as shown in FIG. 9, and the administration of fennel oil significantly inhibited the formation of ulcers.
実施例5
直径5511+11177)濾紙(TOYOADVAN
TBC5A) ニア 、 ンネル油(実施例1と同じ)
30111又は300111を含浸させ、これをイン
ハレーションボックス内に置いた。Example 5 Diameter 5511+11177) Filter paper (TOYOADVAN
TBC5A) Nia, tunnel oil (same as Example 1)
30111 or 300111 was impregnated and placed in an inhalation box.
この中にddy系雄性マウス(5週齢)を入れ30分放
置後、ヘキソパルビタールア0■/kgを腹腔内投与し
、マウスの正向反射を指標として睡眠時間を測定した。A DDY male mouse (5 weeks old) was placed in the solution and left for 30 minutes, after which 0 kg/kg of hexoparbital was administered intraperitoneally, and the sleeping time was measured using the mouse's righting reflex as an index.
結果は第1O図に示すとふりであり、フエ、ンネル油の
投与により有意の睡眠時間延長が認められた。The results are shown in Figure 1O, and a significant extension of sleep time was observed with the administration of fue and tunnel oil.
実施例6 (ガム)
ガムベース
炭酸カルシウム
ステビオサイド
フェンネル油
乳糖
(重量部)
0.1
76.895
全量
実施例7 (飴)
粉末ソルビトール
フェンネル油
香料
99.93 (重量部)
0、Ol
0.01
全量
実施例8 (トローチ)
アラビアゴム
ブドウ糖
フェンネル油
リン酸第二カリウム
リン酸第−カリウム
乳糖
香 料
ステアリン酸マグネシウム
全量
実施例9 (洗口液)
ラウリル硫酸ナトリウム
グリセリン
エチルアルコール
フェンネル油
ソルビトール
香 料
サッカリンナトリウム
水
全量
0、0G5
0.2
0.1
0.005
残量
0.8
0、ロー
0、旧
0、旧
残量
(重量部)
(重量部)
実施例10 (リキュール)
ニュートラルスピリッツ
ステビオサイド
オレンジ果汁
フェンネル油
香 料
0.1
0.01
0.01
(重量部)
全量
実施例11(清涼飲料)
オレンジ果汁
クエン酸ナトリウム
L−アスコルビン酸
フェンネル油
香料
クエン酸
0.2
0.02
0.01
0、ロー
0.2
(重量部)
全量
実施例12 (ジュース)
冷凍オレンジ濃縮果汁
砂糖
5.0
11.0
(重量部)
クエン酸 0.2
し=アスコルビン! 0.02フエンネル
油 0、l
全 量 100実施例1
3(紅茶)
茶菓1.2重量部を適量の湯(80℃)に入れ、十分浸
出させた後、茶殻を濾別し、浸出液に砂糖3.0重量部
、炭酸水素す)IJウム0,08重量部、L−アスコル
ビン酸0.1重量部、フェンネル油1.0重量部を添加
し残余の水(20℃)を加え100重量部とした。Example 6 (Gum) Gum base Calcium carbonate Stevioside Fennel oil Lactose (parts by weight) 0.1 76.895 Total amount Example 7 (Candy) Powdered sorbitol Fennel oil flavoring 99.93 (Parts by weight) 0, Ol 0.01 Total amount carried out Example 8 (lozenge) Gum arabic glucose fennel oil dibasic potassium phosphate dibasic potassium phosphate lactose flavoring magnesium stearate total amount Example 9 (mouth rinse) sodium lauryl sulfate glycerin ethyl alcohol fennel oil sorbitol flavor saccharin sodium water total amount 0 , 0G5 0.2 0.1 0.005 Remaining amount 0.8 0, Low 0, Old 0, Old remaining amount (parts by weight) (parts by weight) Example 10 (Liquor) Neutral Spirits Stevioside Orange Juice Fennel Oil Flavor 0 .1 0.01 0.01 (parts by weight) Total amount Example 11 (soft drink) Orange juice Sodium citrate L-Ascorbic acid Fennel oil Flavor Citric acid 0.2 0.02 0.01 0, Rho 0.2 ( (parts by weight) Total amount Example 12 (Juice) Frozen orange concentrated fruit juice Sugar 5.0 11.0 (parts by weight) Citric acid 0.2 Shi = Ascorbic! 0.02 Fennel oil 0.l Total amount 100 Example 1
3 (Black tea) Put 1.2 parts by weight of tea confectionery into an appropriate amount of hot water (80°C) and infuse it thoroughly, then filter the used tea leaves and add 3.0 parts by weight of sugar and hydrogen carbonate to the infusion solution. 0.08 parts by weight, 0.1 parts by weight of L-ascorbic acid, and 1.0 parts by weight of fennel oil, and the remaining water (20° C.) was added to make 100 parts by weight.
実施例14(ウーロン茶)
茶菓1.2重量部を適量の湯(80℃)に入れ、十分浸
出させた後、茶殻を濾別し、浸出液に炭酸水素ナトリウ
ム0.03重量部、L−アスコルビン酸0.1重量部、
フェンネル油1.0重量部を添加し残余の水(20℃)
を加え100重量部とした。Example 14 (Oolong tea) 1.2 parts by weight of tea confectionery was placed in an appropriate amount of hot water (80°C), and after sufficient infusion, the used tea leaves were filtered and 0.03 parts by weight of sodium bicarbonate and L-ascorbic acid were added to the infusion liquid. 0.1 part by weight,
Add 1.0 parts by weight of fennel oil to the remaining water (20℃)
was added to make 100 parts by weight.
実施例15 (ゼリー)
フェンネル油 0.3(重量部)砂糖
クエン酸ナト
ゼラチン
水
オレンジ果汁
リウム
15.0
0.3
1.1
73、O
全量
実施例16 (乳液)
ステアリン酸
セタノール
ワセリン
ラノリンアルコール
流動パラフィン
スクワラン
エス力ロール507
フェンネル油
20口(10)モノオレート
トリエタノールアミン
プロピレングーリコール
防腐剤
2.0
1.0
3.0
2.0
8.0
3.0
2.0
5.0
2.5
1.0
5.0
適量
(重量部)
蒸留水
全量
実施例17 (栄養クリーム)
ステアリン酸
ステアリルアルコール
還元ラノリン
スクワラン
オクチルドデカノール
POB (25)七チルエーテル
グリセリルモノステアレー
防腐剤
フェンネル油
プロピレングリコール
ド
残量
0G
2.0
7.0
2.0
5.0
6.0
3.0
2.0
適量
2.0
5.0
(重量部)
全量
実施例18 (軟膏)
ステアリルアルコール
モクロウ
フェンネル油
18.0
20.0
0.5
0.25
(重量部)
ポリオキシエチレン千ノ才
レイン酸エステル
ワセリン
40.0
全量
実施例19 (ローション)
フェンネル油
プロピレングリコール
クエン酸
95%エタノール
PUB (20)ラウリルエーテル
1.0
1.0
0.2
1O00
0,5
(重量部)
全量
実施例20(リップト
キャンデリラロウ
固形パラフィン
ミツロウ
カルナバロウ
ラノリン
ヒマシ油
フェンネル油
リートメント)
9.0
8.0
5.0
5.0
11.0
残量
1.0
(重量部)
イソプロピルミリステート10.0
酸化防止剤 適量
全 量 100実施例2
1 (スプレー剤)
エタノール 50(重量部)ジクロロジ
フルオロメタン 49.5
フエンネル油 0.5
全量 100
実施例22(芳香剤)
イソパラフィン 80(重量部)フェンネル
油 20
全量 100
実施例23(芳香剤)
K−カラギーナン粉末 1.1(重量部)ロー
カストビーンガム 1.0
フエンネル油 5.0
水 残量
全量 100
〔発明の効果〕
叙上の如く、本発明製剤の有効成分であるフェンネル油
を鼻粘膜、口腔粘膜又は肺から、特に香気として吸収さ
せると、精神的ストレスにより生ずる疲労及びこれに伴
って発生する潰瘍が有意に予防ないし回復される。Example 15 (Jelly) Fennel oil 0.3 (parts by weight) Sugar Nato citrate Gelatin Water Orange juice Liumium 15.0 0.3 1.1 73, O Total amount Example 16 (Emulsion) Setanol stearate Vaseline Lanolin Alcohol Liquid paraffin Squalane S Power Roll 507 Fennel oil 20 mouths (10) Monooleate Triethanolamine Propylene Glycol Preservative 2.0 1.0 3.0 2.0 8.0 3.0 2.0 5.0 2.5 1 .0 5.0 Appropriate amount (parts by weight) Total amount of distilled water Example 17 (Nutritional cream) Stearic acid stearyl alcohol reduced lanolin squalane octyl dodecanol POB (25) Seventhyl ether glyceryl monostearate preservative fennel oil propylene glycol remaining amount 0G 2.0 7.0 2.0 5.0 6.0 3.0 2.0 Appropriate amount 2.0 5.0 (Parts by weight) Total amount Example 18 (Ointment) Stearyl alcohol Oak fennel oil 18.0 20 .0 0.5 0.25 (Parts by weight) Polyoxyethylene thousand-year-old oleic acid ester petrolatum 40.0 Total amount Example 19 (Lotion) Fennel oil Propylene glycol Citric acid 95% Ethanol PUB (20) Lauryl ether 1.0 1.0 0.2 1000 0.5 (parts by weight) Total amount Example 20 (Ripped candelilla wax solid paraffin beeswax carnauba lanolin castor oil fennel oil treatment) 9.0 8.0 5.0 5.0 11. 0 Remaining amount 1.0 (parts by weight) Isopropyl myristate 10.0 Antioxidant Appropriate amount Total amount 100 Example 2
1 (Spray agent) Ethanol 50 (parts by weight) Dichlorodifluoromethane 49.5 Fennel oil 0.5 Total amount 100 Example 22 (Fragrance agent) Isoparaffin 80 (Parts by weight) Fennel oil 20 Total amount 100 Example 23 (Fragrance agent) K - Carrageenan powder 1.1 (parts by weight) Locust bean gum 1.0 Fennel oil 5.0 Water Total remaining amount 100 [Effects of the invention] As described above, fennel oil, which is the active ingredient of the preparation of the present invention, was applied to the nasal mucosa, When absorbed through the oral mucosa or lungs, especially as a scent, fatigue caused by mental stress and ulcers that occur accompanying this can be significantly prevented or cured.
第1図は被験者に記入式連続計算作業を行わしめたとき
のフェンネル油投与の有無による心拍間隔変動係数の比
較を示し、第2WJは同瞳孔縮瞳率の比較を示し、第3
t!lは同心理状態の比較を示す。
第4図は被験者に連続計算作業を行わしめたときの7エ
ンネル油投与の有無によるVDT心拍呼吸性変動成分の
比較を示し、第51!lは同瞳孔縮瞳率の比較を示し、
第6図は同縮瞳最高速度の比較を示し、第7図は同心理
状態の比較を示す。第8図はフェンネル油投与の有無に
よるマウスの自発運動量の比較を示す。第9図はフェン
ネル油の投与によるストレス潰瘍の抑制効果を示す。第
1O図はフェンネル油投与によるヘキソバルビタール誘
発睡眠時間を示す。
以上
−一きae酬が メ
第
図
)−一一り フェンネル、由投与群
トーーー→フェンネル油非役E+群
末
p<o、os
P<0.1
第
図
緊張
抑E
5つ
活力
疲労
l乱
ロ フェンネル油投与群
ロ フェンネル油非投与群
αφくぜ屯Cχひ一区でもム斌層C甑eRM冊
1!!1tlll[FI!鰹C駆ε l駆コ舅e研 寧
第
図
N=9−10
群
第9
図
!IS暉=嘗:巨
巾
手
続
補
正
書(自発)
平成2年12月17日Figure 1 shows a comparison of the heartbeat interval variation coefficients with and without administration of fennel oil when subjects were asked to perform continuous calculation tasks, the second WJ shows a comparison of the pupil miosis rate, and the third
T! l indicates a comparison of same psychological states. Figure 4 shows a comparison of VDT heart rate and respiratory fluctuation components with and without administration of 7-ennel oil when subjects were made to perform continuous calculation tasks, and the 51st! l indicates a comparison of the same pupil miosis rate,
FIG. 6 shows a comparison of the maximum speed of miosis, and FIG. 7 shows a comparison of the same psychological states. FIG. 8 shows a comparison of locomotor activity of mice with and without administration of fennel oil. FIG. 9 shows the effect of suppressing stress ulcers by administration of fennel oil. FIG. 1O shows hexobarbital-induced sleep duration by administration of fennel oil. The above - one ae reward (Me) - one and one Fennel, Yu administration group - → Fennel oil non-effective E + group end p<o, os P<0.1 Fig. Tension suppression E 5 vitality fatigue l disorder 2. Fennel oil administration group 2. Fennel oil non-administration group αφ Kuzetun C ! 1tllll [FI! Bonito C drive ε l drive Koo e Ken Ning figure N=9-10 Group 9 figure! IS 暉=嘗: Huge procedural amendment (spontaneous) December 17, 1990
Claims (1)
が鼻粘膜、口腔粘膜又は肺から吸収されるような形態に
製剤化されていることを特徴とする精神疲労予防回復剤
。 2、ストレス性潰瘍の予防治療剤である請求項1記載の
精神疲労予防回復剤。[Claims] 1. Prevention and recovery from mental fatigue, characterized in that it contains fennel oil as an active ingredient, and the active ingredient is formulated in a form that is absorbed through the nasal mucosa, oral mucosa, or lungs. agent. 2. The agent for preventing and recovering from mental fatigue according to claim 1, which is a preventive and therapeutic agent for stress ulcers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2249715A JPH04128235A (en) | 1990-09-19 | 1990-09-19 | Mental fatigue preventing and removing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2249715A JPH04128235A (en) | 1990-09-19 | 1990-09-19 | Mental fatigue preventing and removing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04128235A true JPH04128235A (en) | 1992-04-28 |
Family
ID=17197124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2249715A Pending JPH04128235A (en) | 1990-09-19 | 1990-09-19 | Mental fatigue preventing and removing agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04128235A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037092A1 (en) * | 1998-12-21 | 2000-06-29 | The Procter & Gamble Company | Method of using steam ironing of fabrics as a way of causing reduction of physiological and/or subjective reactivity to stress in humans |
WO2007022589A1 (en) * | 2005-08-24 | 2007-03-01 | Neuroscent Pty Ltd | Methods of relieving stress |
-
1990
- 1990-09-19 JP JP2249715A patent/JPH04128235A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037092A1 (en) * | 1998-12-21 | 2000-06-29 | The Procter & Gamble Company | Method of using steam ironing of fabrics as a way of causing reduction of physiological and/or subjective reactivity to stress in humans |
WO2007022589A1 (en) * | 2005-08-24 | 2007-03-01 | Neuroscent Pty Ltd | Methods of relieving stress |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cousens et al. | (−) δ 9 THC as an hypnotic: An experimental study of three dose levels | |
JP5007833B2 (en) | Autonomic nerve regulator | |
DE69636085T2 (en) | Use of gamma-linolenic acid or dihomogammalinolenic acid for the manufacture of a medicament for the treatment of Huntington's chorea | |
Mougin et al. | Effects of sleep disturbances on subsequent physical performance | |
EP1941870B1 (en) | Perfume Composition comprising perilla aldehyde | |
JPH0523245B2 (en) | ||
Haynes et al. | Relaxation treatment of insomnia | |
JP2007519668A (en) | Use of ginkgo complex for cognitive improvement and alleviation of mental fatigue | |
KR101074955B1 (en) | Perfume composition having aromatherapic effect | |
JP2009235015A (en) | Autonomic nerve regulator | |
DE69209414T2 (en) | Preparations that promote brain activity | |
Edmonds Jr et al. | Improved short-term neurological recovery with flunarizine in a canine model of cardiac arrest | |
Gillin et al. | Schizophrenia: Perchance a dream? | |
JPWO2020004182A1 (en) | Sleep improver | |
JPH04128235A (en) | Mental fatigue preventing and removing agent | |
JPH04128234A (en) | Hypnosis promoter | |
JPH0640906A (en) | Sleepiness-suppressing agent | |
US5643928A (en) | Human body weight management | |
JP2018179603A (en) | Estimation method of physiology and psychological effects of scent using psychology, nerve, endocrine, and immunity index | |
JPH11343497A (en) | Cosmetic | |
JP2011037721A (en) | Skin care preparation for external use exhibiting sleep-improving action | |
DE69214979T2 (en) | New, dietary preparations based on phosphorus-lipid complexes and their use in sleep disorders | |
JP6174885B2 (en) | Sleep improver | |
Buchbauer | Lavender oil and its therapeutic properties | |
JPH0640911A (en) | Sleep inducing stimulating agent |